But Entereg’s promise led GlaxoSmithKline, which is a top name in the drug business, to become Adolor’s partner more than six years ago. That’s standard practice in drug development, because Big Pharma has the capital - human and otherwise - that can bring a compound through the FDA approval process onto pharmacy shelves.
Well, yes, it will. The settlement - and last week’s appeals court ruling that overturned a $32 million judgment in Texas - are signs that Merck is working its way through the legal tornado it created when it cranked up the hype machine to sell its Vioxx pain reliever.
While Merck may be scoring points — and limiting monetary damages — with its legal strategy, the company hasn’t fared nearly as well in the court of public opinion.
Congress took aim earlier this month at its integrity over the marketing of Vytorin, a cholesterol-lowering drug it promotes with Schering-Plough Corp.